Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, August 2, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Rachel Vatnsdal Maintained (ADPT) at Buy with Increased Target to $6 on, Aug 2nd, 2024
Rachel Vatnsdal of JP Morgan, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Buy with Increased Target from $5 to $6 on, Aug 2nd, 2024.
Rachel has made no other calls on ADPT in the last 4 months.
There is 1 other peer that has a rating on ADPT. Out of the 1 peers that are also analyzing ADPT, 0 agree with Rachel's Rating of Hold.
This is the rating of the analyst that currently disagrees with Rachel
- Mark Massaro of "BTIG" Maintained at Strong Buy with Decreased Target to $5 on, Thursday, April 4th, 2024
